PhotoCure ASA (FRA:PHS) Quality Rank


FRA:PHS PhotoCure ASA FRA:PHS
74 GF Score
Price €5.23
GF Value €6.35
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

PhotoCure ASA Quality Rank Related Terms

FRA:PHS
74GF Score
PhotoCure ASA FRA:PHS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.23 is trading 17.6% below its estimated GF Value™ of €6.35. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Quality Rank:
  • GF Value™: €6.35 vs. price of €5.23 (17.6% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
74GF Score

Get the complete analysis for FRA:PHS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price
€6.35
GF Value